EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pharmacology of erenumab in human isolated coronary and meningeal arteries: Additional effect of gepants on top of a maximum effect of erenumab

Tessa de Vries iD, Eloísa Rubio-Beltrán, Antoon van den Bogaerdt, Ruben Dammers, A H Jan Danser iD, Josefin Snellman, Jeanine Bussiere, Antoinette MaassenVanDenBrink

British Journal of Pharmacology · 2024

DOI: 10.1111/bph.16322 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, 2024. Verfasst von Tessa de Vries und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Coronary Vessels, Meningeal Arteries, Calcitonin Gene-Related Peptide Receptor Antagonists. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dutch Research Council, Nederlandse Organisatie voor Wetenschappelijk Onderzoek.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose Multiple drugs targeting the calcitonin gene‐related peptide (CGRP) receptor have been developed for migraine treatment. Here, the effect of the monoclonal antibody erenumab on CGRP‐induced vasorelaxation was investigated in human isolated blood vessels, as well as the effect of combining erenumab with the small molecule drugs, namely rimegepant, olcegepant, or sumatriptan. Experimental Approach Concentration–response curves to CGRP, adrenomedullin or pramlintide were constructed in human coronary artery (HCA) and human middle meningeal artery (HMMA) segments, incubated with or without erenumab and/or olcegepant. pA 2 or pK b values were calculated to determine the potency of erenumab in both tissues. To study whether acutely acting antimigraine drugs exerted additional CGRP‐blocking effects on top of erenumab, HCA segments were incubated with a maximally effective concentration of erenumab (3 μM), precontracted with KCl and exposed to CGRP, followed by rimegepant, olcegepant, or sumatriptan in increasing concentrations. Key Results Erenumab shifted the concentration‐response curve to CGRP in both vascular tissues. However, in HCA, the Schild plot slope was significantly smaller than unity, whereas this was not the case in HMMA, indicating different CGRP receptor mechanisms in these tissues. In HCA, rimegepant, olcegepant and sumatriptan exerted additional effects on CGRP on top of a maximal effect of erenumab. Conclusions and Implications Gepants have additional effects on top of erenumab for CGRP‐induced relaxation and could be effective in treating migraine attacks in patients already using erenumab as prophylaxis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedCoronary VesselsMeningeal ArteriesCalcitonin Gene-Related Peptide Receptor AntagonistsSumatriptanHumansMaleMiddle AgedFemaleDose-Response Relationship, DrugPiperidinesAntibodies, MonoclonalCalcitonin Gene-Related PeptideVasodilationPiperazinesQuinazolinesMigraine DisordersIn Vitro TechniquesAgedAdultPyridines

Stichwörter der Autor:innen

CGRPerenumabgepantsmigrainemonoclonal antibodies

Substanzen

erenumabAntibodies, Monoclonal, HumanizedCalcitonin Gene-Related Peptide Receptor AntagonistsSumatriptanolcegepantrimegepant sulfatePiperidinesAntibodies, MonoclonalCalcitonin Gene-Related PeptidePiperazines

Autor:innen und Institutionen

  • Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Heart Valve Department, ETB-BISLIFE, Beverwijk, The Netherlands.
  • Department of Neurosurgery, Erasmus University Medical Center, The Netherlands.
  • Novartis Pharma AG, Basel, Switzerland.
  • Amgen Inc, Thousand Oaks, California, USA.

ORCID-Profile: Tessa de Vries, A H Jan Danser

Förderung

  • Dutch Research Council
  • Nederlandse Organisatie voor Wetenschappelijk Onderzoek

Zitieren

APA

de Vries, T., Rubio-Beltrán, E., van den Bogaerdt, A., Dammers, R., Danser, A. H. J., Snellman, J., Bussiere, J., & MaassenVanDenBrink, A. (2024). Pharmacology of erenumab in human isolated coronary and meningeal arteries: Additional effect of gepants on top of a maximum effect of erenumab. British Journal of Pharmacology. https://doi.org/10.1111/bph.16322

Vancouver

de Vries T, Rubio-Beltrán E, van den Bogaerdt A, Dammers R, Danser AHJ, Snellman J, et al. Pharmacology of erenumab in human isolated coronary and meningeal arteries: Additional effect of gepants on top of a maximum effect of erenumab. British Journal of Pharmacology. 2024. doi:10.1111/bph.16322

BibTeX
@article{deVries2024,
  author = {de Vries, Tessa and Rubio-Beltrán, Eloísa and van den Bogaerdt, Antoon and Dammers, Ruben and Danser, A H Jan and Snellman, Josefin and Bussiere, Jeanine and MaassenVanDenBrink, Antoinette},
  title = {Pharmacology of erenumab in human isolated coronary and meningeal arteries: Additional effect of gepants on top of a maximum effect of erenumab},
  journal = {British Journal of Pharmacology},
  year = {2024},
  doi = {10.1111/bph.16322}
}
Kostenlos starten →